Oncology
7 drugs are in development for Gastric Cancer.
- Companies
- 7
- Clinical trials
- 97
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Gastric Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| ngm120 | NGM BIOPHARMACEUTICALS INC (NGM) |
Phase 1(3)
| Drug | Company |
|---|---|
| AB308 | Arcus Biosciences, Inc. (RCUS) |
| CUE-102 | Cue Biopharma, Inc. (CUE) |
| STRO-004 | SUTRO BIOPHARMA, INC. (STRO) |
Preclinical(1)
| Drug | Company |
|---|---|
| abp-150 | Abpro Holdings, Inc. (ABPO) |
Phase 1/Phase 2(2)
About this indication
Gastric Cancer context
Oncology·MeSH: Stomach Neoplasms (D013274)
Narrower concept of MeSH descriptor Stomach Neoplasms
Prevalence
10.0 / 100K
Incidence
6.1 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Gastric Cancer?
BioSniper tracks 7 drugs in development for Gastric Cancer across 7 companies.
How many clinical trials target Gastric Cancer?
There are 97 clinical trials targeting Gastric Cancer tracked by BioSniper.
What is the prevalence of Gastric Cancer?
The estimated prevalence of Gastric Cancer is approximately 10.0 per 100,000 population.